Cambrex Corporation (NYSE:CBM) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday.

A number of other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. ValuEngine lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $64.00.

Shares of Cambrex Corporation (NYSE CBM) traded down 5.34% on Friday, reaching $58.50. 1,285,934 shares of the company’s stock traded hands. The firm has a market capitalization of $1.91 billion, a P/E ratio of 22.27 and a beta of 2.28. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95. The firm’s 50 day moving average is $58.97 and its 200 day moving average is $55.37.

Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.76. The firm had revenue of $134.55 million for the quarter, compared to analyst estimates of $136.82 million. Cambrex Corporation had a net margin of 17.36% and a return on equity of 24.92%. Cambrex Corporation’s revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.68 EPS. Analysts expect that Cambrex Corporation will post $3.02 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Cambrex Corporation (NYSE:CBM) Rating Increased to Buy at BidaskClub” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/06/cambrex-corporation-nysecbm-rating-increased-to-buy-at-bidaskclub.html.

In other Cambrex Corporation news, Director Leon J. Hendrix, Jr. sold 20,656 shares of the business’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $55.95, for a total transaction of $1,155,703.20. Following the sale, the director now directly owns 74,662 shares in the company, valued at $4,177,338.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $61.39, for a total transaction of $736,680.00. Following the sale, the chief executive officer now owns 95,328 shares in the company, valued at $5,852,185.92. The disclosure for this sale can be found here. Insiders have sold 70,656 shares of company stock worth $4,064,423 over the last quarter. Insiders own 2.48% of the company’s stock.

A number of hedge funds have recently modified their holdings of CBM. BlackRock Inc. raised its stake in shares of Cambrex Corporation by 156,940.2% in the first quarter. BlackRock Inc. now owns 4,002,955 shares of the biotechnology company’s stock worth $220,363,000 after buying an additional 4,000,406 shares during the period. FMR LLC raised its stake in shares of Cambrex Corporation by 78.2% in the first quarter. FMR LLC now owns 899,086 shares of the biotechnology company’s stock worth $49,494,000 after buying an additional 394,638 shares during the period. Norges Bank acquired a new stake in shares of Cambrex Corporation during the fourth quarter worth about $16,903,000. Neumeier Poma Investment Counsel LLC purchased a new stake in Cambrex Corporation during the first quarter worth $16,854,000. Finally, Marshall Wace North America L.P. raised its stake in Cambrex Corporation by 2,239.4% in the second quarter. Marshall Wace North America L.P. now owns 266,106 shares of the biotechnology company’s stock worth $15,966,000 after buying an additional 254,731 shares during the last quarter. Institutional investors own 98.28% of the company’s stock.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.